Andy Chen
Stock Analyst at Wolfe Research
(4.34)
# 1,316
Out of 5,058 analysts
74
Total ratings
46.6%
Success rate
21.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Downgraded: Hold | n/a | $99.21 | - | 4 | Oct 12, 2026 | |
| ROIV Roivant Sciences | Downgraded: Hold | n/a | $34.04 | - | 2 | Oct 12, 2026 | |
| KYMR Kymera Therapeutics | Upgraded: Buy | $180 | $108.14 | +66.45% | 5 | Sep 10, 2026 | |
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | $605 | $459.81 | +31.58% | 3 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $548 → $557 | $508.75 | +9.48% | 5 | Aug 3, 2026 | |
| SYRE Spyre Therapeutics | Downgraded: Hold | n/a | $80.10 | - | 2 | Jul 28, 2026 | |
| IONS Ionis Pharmaceuticals | Downgraded: Hold | n/a | $44.12 | - | 3 | Jul 15, 2026 | |
| NTLA Intellia Therapeutics | Downgraded: Sell | $9 | $11.34 | -20.63% | 5 | Jul 15, 2026 | |
| SRPT Sarepta Therapeutics | Upgraded: Buy | $27 | $17.79 | +51.77% | 2 | Jul 8, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $44 | $28.93 | +52.09% | 4 | Jun 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $176 → $136 | $92.38 | +47.22% | 2 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $28.57 | +208.02% | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $12.01 | +299.67% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $74.39 | +31.74% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $1.54 | +354.55% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $29.64 | +41.70% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $27.51 | +70.85% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 | $10.26 | +133.92% | 5 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $846.27 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.11 | +318.01% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $234.03 | n/a | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $67.13 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $48.71 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $113.27 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $73.87 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $25.40 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $19.56 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $51.52 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $5.53 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0003 | n/a | 2 | Aug 10, 2023 |
Insmed
Oct 12, 2026
Downgraded: Hold
Price Target: n/a
Current: $99.21
Upside: -
Roivant Sciences
Oct 12, 2026
Downgraded: Hold
Price Target: n/a
Current: $34.04
Upside: -
Kymera Therapeutics
Sep 10, 2026
Upgraded: Buy
Price Target: $180
Current: $108.14
Upside: +66.45%
Madrigal Pharmaceuticals
Aug 4, 2026
Upgraded: Buy
Price Target: $605
Current: $459.81
Upside: +31.58%
Vertex Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $548 → $557
Current: $508.75
Upside: +9.48%
Spyre Therapeutics
Jul 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $80.10
Upside: -
Ionis Pharmaceuticals
Jul 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $44.12
Upside: -
Intellia Therapeutics
Jul 15, 2026
Downgraded: Sell
Price Target: $9
Current: $11.34
Upside: -20.63%
Sarepta Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $27
Current: $17.79
Upside: +51.77%
Celldex Therapeutics
Jun 14, 2026
Reiterated: Buy
Price Target: $44
Current: $28.93
Upside: +52.09%
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $92.38
Upside: +47.22%
Jun 2, 2026
Reiterated: Buy
Price Target: $88
Current: $28.57
Upside: +208.02%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $12.01
Upside: +299.67%
Apr 8, 2026
Reiterated: Buy
Price Target: $98
Current: $74.39
Upside: +31.74%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.54
Upside: +354.55%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $29.64
Upside: +41.70%
Apr 6, 2026
Reiterated: Buy
Price Target: $47
Current: $27.51
Upside: +70.85%
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $10.26
Upside: +133.92%
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $846.27
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $3.11
Upside: +318.01%
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $234.03
Upside: n/a
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $67.13
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $48.71
Upside: n/a
Mar 17, 2025
Reiterated: Buy
Price Target: $84
Current: $113.27
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $73.87
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $25.40
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $19.56
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $51.52
Upside: n/a
Oct 25, 2023
Reiterated: Buy
Price Target: $4
Current: $5.53
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0003
Upside: n/a